Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec^®, Gleevec™)

References

• Al SobhiEZahraniZZevallosEImatinib-induced immune hepatitis:case report and literature reviewHematology200712495317364993
   PubMed Web of Science ®Google Scholar
• AliROzkalemkasFOzkanATumour lysis syndrome with acute renal failure during imatinib therapyLeuk Res200731573416782190
   PubMed Web of Science ®Google Scholar
• AliROzkalemkasFOzkocamanVSuccessful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy:a case report and review of the literatureJpn J Clin Oncol200434215715121759
   PubMed Web of Science ®Google Scholar
• AokiEKantarjianHO’BrienSGHigh-dose imatinib provides better responses in patients with untreated early chronic phase CML [abstract]Blood2006108608a
   Web of Science ®Google Scholar
• AtallahEKantarjianHCortesJEmerging safety issues with Imatinib and other Abl tyrosine kinase inhibitorsClin Lymphoma and Myeloma2007a310512
   Google Scholar
• AtallahELKantarjianHO’BrienSUse of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CP-CML) [abstract]J Clin Oncol2007b257006a
   Web of Science ®Google Scholar
• AultPKantarjianHO’BrienSPregnancy among patients with chronic myeloid leukemia treated with imatinibJ Clin Oncol2006241204816446320
   PubMed Web of Science ®Google Scholar
• AzamMLatekRRDaleyGQMechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABLCell20031128314312654249
   PubMed Web of Science ®Google Scholar
• BaccaraniMMartinelliGRostiGImatinib and pegylated human recombinant interferon alpha2b in early chronic-phase chronic myeloid leukemiaBlood200410442455115319292
   PubMed Web of Science ®Google Scholar
• BaccaraniMRostiGde VivoAA randomized study of interferon-alpha versus interferon-alpha and low-dose ara-binosyl cytosine in chronic myeloid leukemiaBlood20029915273511861264
   PubMed Web of Science ®Google Scholar
• BaccaraniMRussoDRostiGInterferon-alfa for chronic myeloid leukemiaSemin Hematol200340223312563609
   PubMed Web of Science ®Google Scholar
• BaccaraniMSaglioGGoldmanJEvolving concepts in the management of chronic myeloid leukemia:recommendations from an expert panel on behalf of the European LeukemiaNetBlood200610818092016709930
   PubMed Web of Science ®Google Scholar
• BarnesDJMeloJVCytogenetic and molecular genetic aspects of chronic myeloid leukaemiaActa Haematol200210818020212432215
   PubMed Web of Science ®Google Scholar
• BarnesDJPalaiologouDPanousopoulouEBcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemiaCancer Res2005658912916204063
   PubMed Web of Science ®Google Scholar
• BartheCCony-MakhoulPMeloJVRoots of clinical resistance to STI-571 cancer therapyScience2001293216311567109
   PubMed Web of Science ®Google Scholar
• BergeronABergotEVilelaGHypersensitivity pneumonitis related to imatinib mesylateJ Clin Oncol2002204271212377975
   PubMed Web of Science ®Google Scholar
• BergstromDAClarkJBXiaoAMK-0457, a novel multikinase inhibitor, inhibits BCR-ABL activity in patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation [abstract]Blood2006108637a
   Web of Science ®Google Scholar
• BermanENicolaidesMMakiRGAltered bone and mineral metabolism in patients receiving imatinib mesylateN Engl J Med200635420061316687713
   PubMed Web of Science ®Google Scholar
• BeumerJHNataleJJLagattutaTFDisposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndromePharmacotherapy200626903716803422
   PubMed Web of Science ®Google Scholar
• BonifaziFde VivoARostiGChronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood20019830748111698293
   PubMed Web of Science ®Google Scholar
• BornhäuserMKrögerNSchwerdtfegerRAllogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib:a retrospective multicentre studyEur J Haematol20067691716343266
   PubMed Web of Science ®Google Scholar
• BorthakurGKantarjianHDaleyGPilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyCancer20061063465216342165
   PubMed Web of Science ®Google Scholar
• BranfordSCrossNCHochhausARationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaLeukemia20062019253016990771
   PubMed Web of Science ®Google Scholar
• BranfordSRudzkiZParkinsonIReal-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsBlood200410429263215256429
   PubMed Web of Science ®Google Scholar
• BranfordSRudzkiZWalshSHigh frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukaemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBlood2002993472511964322
   PubMed Web of Science ®Google Scholar
• BrecciaMMuscaritoliMAversaZImatinib Mesylate may improve fasting blood glucose in diabetic Ph+ Chronic Myelogenous Leukemia patients responsive to treatmentJ Clin Oncol2004224653515542819
   PubMed Web of Science ®Google Scholar
• BuchdungerEZimmermannJMettHInhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivativeCancer Res19965610048548747
   PubMed Web of Science ®Google Scholar
• BurchertAWangYCaiDCompensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance developmentLeukemia20051917748216136169
   PubMed Web of Science ®Google Scholar
• BurgerHvan TolHBoersmaAWImatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood20041042940215251980
   PubMed Web of Science ®Google Scholar
• BurgessMRSkaggsBJShahNPComparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProc Natl Acad Sci2005102339540015705718
   PubMed Web of Science ®Google Scholar
• BuserCAFureyBHooverRContribution of the kinase cross-reactivity profile of MK-0457 to clinical activity [abstract]J Clin Oncol2007257050a
   Web of Science ®Google Scholar
• CarpenterPASnyderDSFlowersMEDProphylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemiaBlood20071092791317119111
   PubMed Web of Science ®Google Scholar
• CarterTAWodickaLMShahNPInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProc Natl Acad Sci200510211011616046538
   PubMed Web of Science ®Google Scholar
• CervantesFHernandez-BoludaJCSteegmannJLImatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon:results and prognostic factors for response and progression-free survival in 150 patientsHaematologica20038811172214555307
   PubMed Web of Science ®Google Scholar
• CheethamGMCharltonPAGolecJMStructural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680Cancer Lett2007118 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• ChoudharyDRMishraPKumarRPregnancy on imatinib:fatal outcome with meningoceleAnn Oncol200617178916291579
   PubMed Web of Science ®Google Scholar
• Chronic Myeloid Leukemia Trialists’ Collaborative GroupInterferon alfa versus chemotherapy for chronic myeloid leukemia:a meta-analysis of seven randomized trialsJ Natl Cancer Inst1997891616209362160
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGJohnsonJRApproval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemiaClin Cancer Res200289354212006504
   PubMed Web of Science ®Google Scholar
• CorbinASLa RoseePStoffregenEPSeveral Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibBlood20031014611412576318
   PubMed Web of Science ®Google Scholar
• CortesJGilesFO’BrienSResult of highdose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaBlood200310283612637317
   PubMed Web of Science ®Google Scholar
• CortesJO’BrienSVerstovsekSPhase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib [abstract]Blood20041041009
   Web of Science ®Google Scholar
• CortesJRousselotPKimDWDasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood200710932071317185463
   PubMed Web of Science ®Google Scholar
• CortesJNatural history and staging of chronic myelogenous leukemiaHematol Oncol Clin North Am2004185698415271393
   PubMed Web of Science ®Google Scholar
• CortesJKantarjianHMBaccaraniMA phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia Chromosome positive (Ph?) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib [abstract]Blood2006108168a
   Web of Science ®Google Scholar
• Cowan-JacobSWGuezVFendrichGImatinib (STI571) resistance in chronic myelogenous leukemia:molecular basis of the underlying mechanisms and potential strategies for treatmentMini Rev Med Chem200442859915032675
   PubMed Web of Science ®Google Scholar
• CraigARKantarjianHCotesEA phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph?) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib [abstract]J Clin Oncol2007257046a
   Web of Science ®Google Scholar
• CrossTJBagotCPortmannBImatinib mesylate as a cause of acute liver failureAm J Hematol2006811899216493605
   PubMed Web of Science ®Google Scholar
• DaiYRahmaniMCoreySJA Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2J Biol Chem2004279342273915175350
   PubMed Web of Science ®Google Scholar
• DeAngeloDJHochbergEPAlyeaEPExtended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation:durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host diseaseClin Cancer Res20041050657115297408
   PubMed Web of Science ®Google Scholar
• de GrootJWBLinksTPvan der GraafWTATyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxineAnn Oncol20061717192016731538
   PubMed Web of Science ®Google Scholar
• de GrootJZonnenbergBPlukkerWImatinib induces hypothyroidism in patients receiving levothyroxineClin Pharmacol Ther200578433816198662
   PubMed Web of Science ®Google Scholar
• DeiningerMWGoldmanJMLydonNThe tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cellsBlood199790369189345054
   PubMed Web of Science ®Google Scholar
• DeiningerMWO’BrienSGFordJMPractical management of patients with chronic myeloid leukemia receiving imatinibJ Clin Oncol20032116374712668652
   PubMed Web of Science ®Google Scholar
• DeiningerMWSchleuningMGreinixHThe effect of prior exposure to imatinib on transplant-related mortalityHaematologica200691452916585011
   PubMed Web of Science ®Google Scholar
• DeiningerMWChronic myeloid leukemia. Management of early stage diseaseHematology20051748216304377
   PubMedGoogle Scholar
• DenglerJvon BubnoffNDeckerTCombination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinibLeukemia2005191835815990864
   PubMed Web of Science ®Google Scholar
• DewarALFarrugiaANCondinaMRImatinib as a potential antiresorptive therapy for bone diseaseBlood20061074334716449525
   PubMed Web of Science ®Google Scholar
• Dhalluin-VenierVBessonCDimetSImatinib mesylate-induced acute hepatitis with autoimmune featuresEur J Gastroenterol Hepatol2006181235717033447
   PubMed Web of Science ®Google Scholar
• DonatoNJWuJYStapleyJBCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood2003101690812509383
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med200635524081717151364
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med20013441031711287972
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med1996256168616716
   PubMed Web of Science ®Google Scholar
• EbnoetherMStentoftJFordJCerebral oedema as a possible complication of treatment with imatinibLancet20023591751212049868
   PubMed Web of Science ®Google Scholar
• FaderlSTalpazMEstrovZChronic myelogenous leukemia:biology and therapyAnn Intern Med1999a1312071910428738
   PubMed Web of Science ®Google Scholar
• FaderlSTalpazMEstrovZThe biology of chronic myeloid leukemiaN Engl J Med1999b3411647210403855
   PubMed Web of Science ®Google Scholar
• FerreroDPoglianiEMRege-CambrinGCorticosteroids can reverse severe imatinib-induced hepatotoxicityHaematologica200691357
   Web of Science ®Google Scholar
• GambacortiCTalpazMSawyersCFive year follow-up results of a phase II trial in patients with late chronic phase chronic myeloid leukemia treated with Imatinib who are refractory/intolerant of Interferon-α [abstract]Blood20051061089a
   Web of Science ®Google Scholar
• Gambacorti-PasseriniCBrummendorfTKantarjianHBosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib [abstract]J Clin Oncol2007257006a
   Web of Science ®Google Scholar
• Gambacorti-PasseriniCZucchettiMRussoDAlpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patientsClin Cancer Res200396253212576428
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCBarniRle CoutrePRole of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(?) leukemic cells to the abl inhibitor STI571J Natl Cancer Inst20009216415011036109
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCle CoutrePMologniLInhibition of the ABL kinase activity blocks the proliferation of BCR/ABL? leukemic cells and induces apoptosisBlood Cells Mol Dis199723380949446752
   PubMed Web of Science ®Google Scholar
• GardembasMRousselotPTulliezMResults of a prospective phase 2 study combining Imatinib Mesylate and Cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phaseBlood2003102429830512933584
   PubMed Web of Science ®Google Scholar
• GardnerERBurgerHvan SchaikRHAssociation of enzyme and transporter genotypes with the pharmacokinetics of imatinibClin Pharmacol Ther20068019220116890580
   PubMed Web of Science ®Google Scholar
• GilesFle CoutrePBhallaKA phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib [abstract]J Clin Oncol2007a257038a
   Web of Science ®Google Scholar
• GilesFCortesJBergstromDAMK–0457, a novel Aurora Kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant Chronic Myelogenous Leukemia (CML) [abstract]Blood2006b108163a
   Web of Science ®Google Scholar
• GilesFle CoutrePBhallaKA phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to patients with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed Dasatinib therapy [abstract]Blood2006a1082170a
   Web of Science ®Google Scholar
• GilesFJCortesJJonesDMK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutationBlood2007b109500216990603
   PubMed Web of Science ®Google Scholar
• GiraltSAroraMGoldmanJMImpact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaBrit J Haematol2007137461717459051
   PubMed Web of Science ®Google Scholar
• GorreMEMohammedMEllwoodKClinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationScience20012938768011423618
   PubMed Web of Science ®Google Scholar
• GratwohlASchmidOBaldomeroHHaematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity surveyBone Marrow Transplant2004348557515517006
   PubMed Web of Science ®Google Scholar
• GratwohlABrandRApperleyJAllogeneic hematopoietic SCT for chronic myeloid leukemia in Europe 2006:transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Haematologica2006915132116533723
   PubMed Web of Science ®Google Scholar
• GratwohlAHermansJGoldmanJMRisk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLancet19983521087929798583
   PubMed Web of Science ®Google Scholar
• GreyAO’SullivanSReidIRImatinib mesylate, increased bone formation, and secondary hyperparathyroidismN Engl J Med20063552494517151376
   PubMed Web of Science ®Google Scholar
• GriswoldIJMacPartlinMBummTKinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinibMol Cell Biol20062660829316880519
   PubMed Web of Science ®Google Scholar
• GschwindHPPfaarUWaldmeierFMetabolism and disposition of imatinib mesylate in healthy volunteersDrug Metab Dispos20053315031216006570
   PubMed Web of Science ®Google Scholar
• GuglielmiCArceseWDazziFDonor lymphocyte infusion for relapsed chronic myelogenous leukemia:prognostic relevance of the initial cell doseBlood200210039740512091328
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJKimDWDasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood2007130 Epub ahead of print
   Web of Science ®Google Scholar
• GuilhotFChastangCMichalletMInterferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study GroupN Engl J Med199733722399227927
   PubMed Web of Science ®Google Scholar
• GumireddyKBakerSJCosenzaSCA non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceProc Natl Acad Sci USA20051021992715677719
   PubMed Web of Science ®Google Scholar
• HambergFde JongFABoonstraJGNon-islet-cell tumor induced hypoglycemia in patients with advanced Gastrointestinal Stromal Tumor possibly worsened by ImatinibJ Clin Oncol200624e30e3116782905
   PubMedGoogle Scholar
• HardanIAmariglioNTrakhtenbrotLTowards stopping Imatinib therapy under the umbrella of Interferone:Alpha-Interferone improves molecular response in CML patients with Imatinib induced complete cytogenetic remission:An early observation from a study of pegylated Interferone in the setup of minimal residual diseaseBlood20061084788a
   Web of Science ®Google Scholar
• HarringtonEABebbingtonDMooreJVX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivoNat Med200410262714981513
   PubMed Web of Science ®Google Scholar
• HasfordJPfirrmannMHehlmannRA new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project GroupJ Natl Cancer Inst19989085089625174
   PubMed Web of Science ®Google Scholar
• HehlmannRBergerUHochhausAChronic myeloid leukemia:a model for oncologyAnn Hematol2005844879715931535
   PubMed Web of Science ®Google Scholar
• HehlmannRBergerUPfirrmannMDrug treatment is superior to allografting as first line therapy in chronic myeloid leukemiaBlood2007222 Epub ahead of print
   Web of Science ®Google Scholar
• HehlmannRHeimpelHHasfordJRandomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia:prolongation of survival by hydroxyurea. The German CML Study GroupBlood1993823984078329700
   PubMed Web of Science ®Google Scholar
• HehlmannRHeimpelHHasfordJRandomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study GroupBlood1994844064777994025
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood20071092303917138817
   PubMed Web of Science ®Google Scholar
• HochhausAKimDWRousselotPDasatinib (SPRYCEL®) 50 mg or 70 mg BID versus 100 mg or 140 mg QD in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to Imatinib: Results of the CA180-034 Study [abstract]Blood2006108166a
   Web of Science ®Google Scholar
• HochhausAKreilSCorbinASMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia2002162190612399961
   PubMed Web of Science ®Google Scholar
• HochhausALinFReiterAVariable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alphaBr J Haematol19959126317577619
   PubMed Web of Science ®Google Scholar
• HochhausALinFReiterAQuantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reactionBlood1996871549558608246
   PubMed Web of Science ®Google Scholar
• HochhausAReiterASausseleSGerman CML Study Group and the UK MRC CML Study GroupMolecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia:low levels of minimal residual disease are associated with continuing remissionBlood20009562610607685
   PubMed Web of Science ®Google Scholar
• HofmannWKKomorMWassmannBPresence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph? acute lymphoblastic leukemiaBlood20031026596112663457
   PubMed Web of Science ®Google Scholar
• HooverRRMahonFXMeloJVOvercoming STI571 resistance with the farnesyl transferase inhibitor SCH66336Blood200210010687112130526
   PubMed Web of Science ®Google Scholar
• HoughtonPJGermainGSHarwoodFCImatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitroCancer Res2004642333715059881
   PubMed Web of Science ®Google Scholar
• HsiaoLTChungHMLinJTStevens-Johnson syndrome after treatment with STI571: A case reportBr J Haematol2002117620212028031
   PubMed Web of Science ®Google Scholar
• HuYLiuYPelletierSRequirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemiaNat Genet2004364536115098032
   PubMed Web of Science ®Google Scholar
• HughesTBranfordSReynoldsJHigher dose Imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase:cytogenetic response rates at 12 months are superior to IRIS [abstract]Blood20041041001a
   Web of Science ®Google Scholar
• HughesTDeiningerMHochhausAMonitoring CML patients responding to treatment with tyrosine kinase inhibitors:review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood2006108283716522812
   PubMed Web of Science ®Google Scholar
• HughesTABL Kinase inhibitor therapy for CML:baseline assessments and response monitoringHematology20062111717124063
   PubMedGoogle Scholar
• HughesTPBranfordSReynoldsJMaintenance of Imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point [abstract]Blood2005106164a
   Web of Science ®Google Scholar
• HughesTPKaedaJBranfordSFrequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaN Engl J Med200334914233214534335
   PubMed Web of Science ®Google Scholar
• IllmerTSchaichMPlatzbeckerUP-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylateLeukemia200418401814724652
   PubMed Web of Science ®Google Scholar
• InokuchiKChronic myelogenous leukemia:from molecular biology to clinical aspects and novel targeted therapiesJ Nippon Med Sch2006731789216936444
   PubMedGoogle Scholar
• IssaJPGharibyanVCortesJPhase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJ Clin Oncol20052339485615883410
   PubMed Web of Science ®Google Scholar
• IssaadCAhmedMNovaultSBiological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7Leukemia2000146627010764152
   PubMed Web of Science ®Google Scholar
• IsshikiIYamaguchiKOkamotoSInterstitial pneumonitis during imatinib therapyBr J Haematol200412542015142112
   PubMedGoogle Scholar
• JaysonGCParkerGJMullamithaSBlockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volumeJ Clin Oncol2005239738115466784
   PubMed Web of Science ®Google Scholar
• JabbourEle CoutrePBaccaraniMNilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]J Clin Oncol2007257039a
   Web of Science ®Google Scholar
• JoensuuHReichardtPCorrespondence:Imatinib and Altered Bone and Mineral MetabolismN Engl J Med200635562816903020
   PubMed Web of Science ®Google Scholar
• JonuleitTPeschelCSchwabRBcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factorsBr J Haematol19981002953039488616
   PubMed Web of Science ®Google Scholar
• JonuleitTvan der KuipHMiethingCBcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell linesBlood2000961933910961897
   PubMed Web of Science ®Google Scholar
• JorgensenHGAllanEKGrahamSMLonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitroLeukemia20051911849115889158
   PubMed Web of Science ®Google Scholar
• KantarjianHCortesJO’BrienSLong-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon alphaBlood2004a10419798815198956
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFWunderleLNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med2006a35425425116775235
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSTalpazMOutcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failureCancer2007b10915566017342766
   PubMed Web of Science ®Google Scholar
• KantarjianHPasquiniRHamerschlakNDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib:a randomized phase-II trialBlood2007a222 Epub ahead of print
   Web of Science ®Google Scholar
• KantarjianHSawyersCHochhausAHematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaN Engl J Med2002a3466455211870241
   PubMed Web of Science ®Google Scholar
• KantarjianHTalpazMO’BrienSImatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha:follow-up resultsClin Cancer Res2002b821778712114418
   PubMed Web of Science ®Google Scholar
• KantarjianHTalpazMO’BrienSDose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaBlood2003a101473512393385
   PubMed Web of Science ®Google Scholar
• KantarjianHTalpazMO’BrienSHigh-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaBlood2004b1032873815070658
   PubMed Web of Science ®Google Scholar
• KantarjianHMGattermannNHochhausAA phase II study of Nilotinib a novel tyrosine kinase Inhibitor administered to Imatinib-resisbtant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]Blood2006b1082169a
   Web of Science ®Google Scholar
• KantarjianHMO’BrienSCortesJEImatinib mesylate therapy for relapse after allogeneic SCT for chronic myelogenous leukemiaBlood2002c1001590512176876
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSCortesJResults of decitabine (5-aza-2’deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaCancer2003b98522812879469
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSSmithTLTreatment of philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabineJ Clin Oncol1999172849210458244
   PubMed Web of Science ®Google Scholar
• KeeshanKMillsKICotterTGMcKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotypeLeukemia20011518233311753601
   PubMed Web of Science ®Google Scholar
• KerkelaRGrazetteLYacobiRCardiotoxicity of the cancer therapeutic agent imatinib mesylateNat Med2006129081616862153
   PubMed Web of Science ®Google Scholar
• KimDWChungYJLeeSPretransplant Imatinib can improve the outcome of non myeloablative SCT without increasing the mortality in Philadelphia-chromosome positive chronic myeloid leukemiaLeukemia2004181907915356641
   PubMed Web of Science ®Google Scholar
• Kluin-NelemansHCBuckGle CessieSRandomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groupsBlood200410344081515010373
   PubMed Web of Science ®Google Scholar
• KoleskeAJGiffordAMScottMLEssential roles for the Abl and Arg tyrosine kinases in neurulationNeuron1998211259729883720
   PubMed Web of Science ®Google Scholar
• KuhrTBurgstallerSApfelbeckUA randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)Leuk Res2003274051112620292
   PubMed Web of Science ®Google Scholar
• KuwanoYAsahinaAWatanabeRHeliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemiaInt J Dermatol20064512495117040457
   PubMed Web of Science ®Google Scholar
• LarsonRADrukerBJGuilhotFCorrelation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib – an analysis of IRIS study dataBlood2006108429a
   Web of Science ®Google Scholar
• le CoutrePBhallaKGilesGA phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukenia (CML) in chronic phase (CP) [abstract]J Clin Oncol2007257007a
   Web of Science ®Google Scholar
• le CoutrePKreuzerKANaIKDetermination of alpha-1 acid glycoprotein in patients with Ph? chronic myeloid leukemia during the first 13 weeks of therapy with STI571Blood Cells Mol Dis200228758511987244
   PubMed Web of Science ®Google Scholar
• le CoutrePTassiEVarella-GarciaMInduction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationBlood20009517586610688835
   PubMed Web of Science ®Google Scholar
• LeeSJChronic myelogenous leukaemiaBr J Haematol2000111993100911167734
   PubMed Web of Science ®Google Scholar
• LinNUSarantopoulosSStoneJRFatal hepatic necrosis following imatinib mesylate therapyBlood20031023455614568907
   PubMed Web of Science ®Google Scholar
• LindahlPJohanssonBRLeveenPPericyte loss and microaneurysm formation in PDGF-B-deficient miceScience199727724259211853
   PubMed Web of Science ®Google Scholar
• LionbergerJMWilsonMBSmithgallTETransformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective HckJ Biol Chem200027518581510849448
   PubMed Web of Science ®Google Scholar
• LyCArechigaAFMeloJVBcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycinCancer Res20036357162214522890
   PubMed Web of Science ®Google Scholar
• MaCXHobdayTJJettJRImatinib mesylate-induced interstitial pneumonitsMayo Clin Proc2003781578914661689
   PubMed Web of Science ®Google Scholar
• MahonFXDeiningerMWSchultheisBChabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:diverse mechanisms of resistanceBlood2000961070910910924
   PubMed Web of Science ®Google Scholar
• MarinDMarktelSFootNGranulocyte colony-stimulation factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylateHaematologica200388227912604417
   PubMed Web of Science ®Google Scholar
• MartinJMJordaEMonteagudoCFollicular acneiform eruption induced by imatinibJ Eur Acad Dermatol Venereol20062013687017062082
   PubMed Web of Science ®Google Scholar
• MartinelliGSoveriniSIacobucciIMK-0457:a light at the end of the tunnel ?Blood20071093967
   Web of Science ®Google Scholar
• MatthewsNVisintinCHartzoulakisBAurora A and B kinases as targets for cancer:will they be selective for tumors?Expert Rev Anticancer Ther200661092016375648
   PubMed Web of Science ®Google Scholar
• MedeirosBCLiptonJHChlordiazepoxide for imatinib-induced muscular crampsEur J Haematol20067753817105448
   PubMed Web of Science ®Google Scholar
• MichalletMMaloiselFDelainMPegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia:a phase III studyLeukemia2004183091514671645
   PubMed Web of Science ®Google Scholar
• MohiMGBoultonCGuTLCombination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKsProc Natl Acad Sci USA20041013130514976243
   PubMed Web of Science ®Google Scholar
• MullerMCLahayeTHochhausAResistance to tumor specific therapy with imatinib by clonal selection of mutated cellsDtsch Med Wochenschr20021272205712397549
   PubMed Web of Science ®Google Scholar
• NagarBBornmannWGPellicenaPCrystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)Cancer Res20026242364312154025
   PubMed Web of Science ®Google Scholar
• NakanishiTShiozawaKHasselBAComplex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells:BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expressionBlood20061086788416543472
   PubMed Web of Science ®Google Scholar
• NguyenTTMohrbacherAFTsaiYCQuantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia:biological implicationsBlood2000952990210779450
   PubMed Web of Science ®Google Scholar
• NowellPCHungerfordDAChromosome studies on normal and leukemic human leukocytesJ Natl Cancer Inst1960258510914427847
   PubMed Web of Science ®Google Scholar
• O’HareTEideCEDeiningerMWNBcr-Abl Kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemiaBlood2007511 Epub ahead of print
   Web of Science ®Google Scholar
• O’HareTWaltersDKStoffregenEPIn vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsCancer Res2005654500515930265
   PubMed Web of Science ®Google Scholar
• O’BrienSKantarjianHTalpazMPractical guidelines for the management of chronic myelogenous leukemia with interferon alphaLeuk Lymphoma199623247529031105
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2003348994100412637609
   PubMed Web of Science ®Google Scholar
• OehlerVGGooleyTSnyderDSThe effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaBlood200710917828917062727
   PubMed Web of Science ®Google Scholar
• OetzelCJonuleitTGotzAThe tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-XClin Cancer Res2000619586810815921
   PubMed Web of Science ®Google Scholar
• OhnishiKSakaiFKudohSTwenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylateLeukemia2006201162416598305
   PubMed Web of Science ®Google Scholar
• OhyashikiKKuriyamaYNakajimaAImatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitisLeukemia2002162160112357373
   PubMed Web of Science ®Google Scholar
• OkiYKantarjianHMGharibyanVPhase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemiaCancer200710989990617236224
   PubMed Web of Science ®Google Scholar
• OlavarriaEOttmannOGDeiningerMResponse to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemiaLeukemia20031717071212970768
   PubMed Web of Science ®Google Scholar
• OttmannOKantarjianHMLarsonRA phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to Imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]Blood20061081862a
   Web of Science ®Google Scholar
• OwenSHatfieldALetvakLCorrespondence:Imatinib and Altered Bone and Mineral MetabolismN Engl J Med200635562716899786
   PubMed Web of Science ®Google Scholar
• Ozvegy-LaczkaCHegedusTVaradyGHigh-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporterMol Pharmacol20046514859515155841
   PubMed Web of Science ®Google Scholar
• PasswegJRWalkerISobocinskiKAValidation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia receiving allogeneic haematopoietic stem cell transplantsBr J Haematol20041256132015147377
   PubMed Web of Science ®Google Scholar
• PavithranKThomasMImatinib induced Stevens-Johnson syndrome:lack of recurrence following re-challenge with a lower doseIndian J Dermatol Venereol Leprol200571288916394445
   PubMedGoogle Scholar
• PengBHayesMRestaDPharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patientsJ Clin Oncol2004229354214990650
   PubMed Web of Science ®Google Scholar
• PengBLloydPSchranHClinical pharmacokinetics of imatinibClin Pharmacokinet2005448799416122278
   PubMed Web of Science ®Google Scholar
• PetersDGHooverRRGerlachMJActivity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemiaBlood20019714041211222387
   PubMed Web of Science ®Google Scholar
• PetzerALEavesCJLansdorpPMCharacterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemiaBlood1996882162718822936
   PubMed Web of Science ®Google Scholar
• PfeiferHWassmannBPavlovaAKinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph? ALL)Blood200743 Epub ahead of print
   Web of Science ®Google Scholar
• PicardSTitierKEtienneGTrough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood20071093496917192396
   PubMed Web of Science ®Google Scholar
• PilotPRSablinskaKOwenSEpidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinibLeukemia20062014816292349
   PubMed Web of Science ®Google Scholar
• PopescuLMVidulescuCCuriciAImatinib inhibits spontaneous rhythmic contractions of human uterus and intestineEur J Pharmacol20065461778116919263
   PubMed Web of Science ®Google Scholar
• PrabhashKSastryPSBiswasGPregnancy outcome of two patients treated with imatinibAnn Oncol2005161983416100234
   PubMed Web of Science ®Google Scholar
• PtasznikANakataYKalotaAEmerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(?) leukemia cellsNat Med2004101187915502840
   PubMed Web of Science ®Google Scholar
• PyeSCortesJRostiGImatinib and Pregnancy [abstract]Blood2006108431a
   Web of Science ®Google Scholar
• RadichJPGooleyTBensingerWHLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimenBlood200310231512595317
   PubMed Web of Science ®Google Scholar
• RayACowan-JacobSWManleyPIdentification of Bcr-Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis studyBlood2007215 Epub ahead of print
   Web of Science ®Google Scholar
• RobertCSoriaJCSpatzACutaneous side-effects of kinase inhibitors and blocking antibodiesLancet Oncology2005649150015992698
   PubMed Web of Science ®Google Scholar
• Roche-LestienneCSoenen-CornuVGrardel-DuflosNSeveral types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood20021001014812130516
   PubMed Web of Science ®Google Scholar
• RosadoMFDonnaEAhnYSChallenging problems in advanced malignancy:case 3. Imatinib mesylate-induced interstitial pneumonitisJ Clin Oncol2003213171312915610
   PubMed Web of Science ®Google Scholar
• RostiGMartinelliGBassiSMolecular response to imatinib in late chronic phase chronic myeloid leukemiaBlood200410322849014645009
   PubMed Web of Science ®Google Scholar
• RowleyJDLetter:A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa stainingNature197324329034126434
   PubMed Web of Science ®Google Scholar
• RoyLGuilhotJKrahnkeTSurvival advantage from imatinib compared with the combination interferon alpha plus cytarabine in chronic-phase chronic myelogenous leukemia:historical comparison between two phase 3 trialsBlood200610814788416627756
   PubMed Web of Science ®Google Scholar
• RoyLGuilhotJMartineauGUnexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemiaLeukemia20051916899216015386
   PubMed Web of Science ®Google Scholar
• RuleSAO’BrienSGCrossmanLCManaging cutaneous reactions to imatinib therapyBlood20021003434512412577
   PubMed Web of Science ®Google Scholar
• SacchiSKantarjianHO’BrienSImmune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemiaJ Clin Oncol199513240177666100
   PubMed Web of Science ®Google Scholar
• SamantaAKLinHSunTJanus kinase 2:a critical target in chronic myelogenous leukemiaCancer Res20066664687216818614
   PubMed Web of Science ®Google Scholar
• Sanchez-GonzalezBPascual-RamirezJCFernandez-AbellanPSevere skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemiaBlood2003101244612609964
   PubMed Web of Science ®Google Scholar
• SawyersCLCallahanWWitteONDominant negative MYC blocks transformation by ABL oncogenesCell199270901101525828
   PubMed Web of Science ®Google Scholar
• SawyersCLHochhausAFeldmanEImatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis:results of a phase 2 studyBlood2002993530911986204
   PubMed Web of Science ®Google Scholar
• SawyersCLChronic myeloid leukemiaN Engl J Med199934013304010219069
   PubMed Web of Science ®Google Scholar
• ScheinfeldNImatinib mesylate and dermatopathy part 2:a review of the cutaneous side effects of imatinib mesylateJ Drugs Dermatol200652283116573254
   PubMedGoogle Scholar
• SchellingsMWLowenbergBPintoYMAnother Look at Imatinib MesylateNew Engl J of Med2007356118317361003
   PubMed Web of Science ®Google Scholar
• SchindlerTBornmannWPellicenaPStructural mechanism for STI-571 inhibition of abelson tyrosine kinaseScience200028919384210988075
   PubMed Web of Science ®Google Scholar
• SchmidliHPengBRiviereGJPopulation pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia:results of a phase III studyBr J Clin Pharmacol200560354415963092
   PubMed Web of Science ®Google Scholar
• SchwartzbergPLStallAMHardinJDMice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populationsCell1991651165752065353
   PubMed Web of Science ®Google Scholar
• SeymourJFGriggAReynoldsJTwo year data from a prospective safety study analyzing the consequences of Imatinib Mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML [abstract]Blood20061082147a
   Web of Science ®Google Scholar
• ShahNPNicollJMNagarBMultiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell200221172512204532
   PubMed Web of Science ®Google Scholar
• ShahNPTranCLeeFYOverriding imatinib resistance with a novel ABL kinase inhibitorScience200430539940115256671
   PubMed Web of Science ®Google Scholar
• ShahNPSkaggsBBranfordSSequential kinase inhibitor iherapy in CML patients can select for cells harboring compound BCR-ABL kinase domain mutations with increased oncogenic potency:Rationale for early combination therapy of ABL kinase inhibitors [abstract]Blood2006a108751a
   Web of Science ®Google Scholar
• ShahNPSkaggsBBranfordSThe most common Dasatinib-resistant BCR-ABL kinase domain mutations in patients with Chronic Myeloid Leukemia are sensitive to VX-680:Rationale for early combination kinase inhibitor therapy [abstract]Blood2006b1082175a
   Web of Science ®Google Scholar
• ShimoniAKrögerNZanderARImatinib mesylate (STI571) in preparation for allogeneic hematopoietic SCT and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemiasLeukemia200317290712592325
   PubMed Web of Science ®Google Scholar
• SilverRTPetersonBLSzatrowskiTPTreatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine:results from CALGB study 9013Leuk Lymphoma200344394812691141
   PubMed Web of Science ®Google Scholar
• SilverRTTalpazMSawyersCLFour years of follow-up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with Imatinib in three large phase II trials [abstract]Blood200410423a
   Google Scholar
• SilverRTWoolfSHHehlmannRAn evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyBlood19999415173610477676
   PubMed Web of Science ®Google Scholar
• SkaggsBJGorreMERyvkinAPhosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsProc Natl Acad Sci USA2006103194667117164333
   PubMed Web of Science ®Google Scholar
• SokalJECoxEBBaccaraniMPrognostic discrimination in good-risk chronic granulocytic leukemiaBlood198463789996584184
   PubMed Web of Science ®Google Scholar
• SoveriniSTascoGGrafoneTBinding mode of the tyrosine kinase inhibitor bosutinib (SKI-606) to Abl kinase [abstract]J Clin Oncol2007257049a
   Web of Science ®Google Scholar
• SoveriniSColarossiSGnaniAContribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients:by the GIMEMA Working Party on Chronic Myeloid LeukemiaClin Cancer Res2006127374917189410
   PubMed Web of Science ®Google Scholar
• StylianAFennelyETButlerJPAllogeneic transplant outcomes in Imatinib-refractory chronic myeloid leukaemia (CML) are similar to transplant outcomes in Imatinib-responsive / Imatinib-naive CML and appear to be predicted by the EBMT risk score [abstract]Blood20061083155a
   Web of Science ®Google Scholar
• SuppiahRKalaycioMSuccessful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimesterLeuk Lymphoma20064711495016840209
   PubMed Web of Science ®Google Scholar
• TalpazMKantarjianHKurzrockRInterferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patientsAnn Intern Med199111453282001086
   PubMed Web of Science ®Google Scholar
• TalpazMKantarjianHMMcCredieKBHematologic remission and cytogenetic improvement induced by recombinant human interferon-α in chronic myelogenous leukemiaN Engl J Med1986314106593457264
   PubMed Web of Science ®Google Scholar
• TalpazMMcCredieKBMavligitGMLeukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemiaBlood198362689926192858
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianHDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med200635425314116775234
   PubMed Web of Science ®Google Scholar
• TalpazMSilverRTDrukerBJImatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia:results of a phase 2 studyBlood20029919283711877262
   PubMed Web of Science ®Google Scholar
• The Benelux CML Study GroupRandomized Study on Hydroxyurea alone versus Hydroxyurea combined with low-dose Interferon-2b for Chronic Myeloid LeukemiaBlood1998912713219531580
   PubMed Web of Science ®Google Scholar
• ThomasJWangLClarkREActive transport of imatinib into and out of cells:implications for drug resistanceBlood200410437394515315971
   PubMed Web of Science ®Google Scholar
• TokarskiJSNewittJAChangCYThe structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutantsCancer Res2006665790716740718
   PubMed Web of Science ®Google Scholar
• van der KuipHMoehringAWohlboldLImatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell linesLeuk Res200428405815109541
   PubMed Web of Science ®Google Scholar
• van der KuipHWohlboldLOetzelCMechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinasesAm J Pharmacogenomics200551011215813673
   PubMedGoogle Scholar
• VardimanJWHarrisNLBrunningRDThe World Health Organization (WHO) classification of the myeloid neoplasmsBlood2002100229230212239137
   PubMed Web of Science ®Google Scholar
• VidalDPuigLSuredaASTI571-Induced Stevens-Johnson syndromeBr J Haematol2002119274512358937
   PubMed Web of Science ®Google Scholar
• von BubnoffNSchnellerFPeschelCBCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyLancet20023594879111853795
   PubMed Web of Science ®Google Scholar
• von BubnoffNVeachDRvan der KuipHA cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitorBlood20051051652915459011
   PubMed Web of Science ®Google Scholar
• WangYCaiDBrendelCAdaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL? progenitors via JAK-2/STAT-5 pathway activationBlood200710921475517090651
   PubMed Web of Science ®Google Scholar
• WeisbergEGriffinJDMechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patientsDrug Resist Updat2001422811512149
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPMestanJAMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBr J Cancer2006941765916721371
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPWBreitensteinWCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell200571294115710326
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPCowan-JacobSWSecond generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemiaNature Reviews Cancer2007734556
   PubMed Web of Science ®Google Scholar
• WeisdorfDJAnasettiCAntinJHAllogeneic bone marrow transplantation for chronic myelogenous leukemia:comparative analysis of unrelated versus matched sibling donor transplantationBlood20029919717711877268
   PubMed Web of Science ®Google Scholar
• WeisserMSchleuningMHaferlachCAllogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapyLeuk Lymphoma20074819520117325868
   PubMed Web of Science ®Google Scholar
• WetzlerMKantarjianHKurzrockRInterferon-alpha therapy for chronic myelogenous leukemiaAm J Med199599402117573097
   PubMed Web of Science ®Google Scholar
• WilkinsonGRDrug metabolism and variability among patients in drug responseN Engl J Med200535222112115917386
   PubMed Web of Science ®Google Scholar
• WillisSGLangeTDemehriSHigh-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients:correlation with clonal cytogenetic evolution but not response to therapyBlood200510621283715914554
   PubMed Web of Science ®Google Scholar
• WohlboldLvan der KuipHMiethingCInhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)Blood20031022236912750174
   PubMed Web of Science ®Google Scholar
• XieSLinHSunTJak2 is involved in c-Myc induction by Bcr-AblOncogene20022171374612370803
   PubMed Web of Science ®Google Scholar
• XieSWangYLiuJInvolvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformationOncogene20012061889511593427
   PubMed Web of Science ®Google Scholar
• YokotaAKimuraSMasudaSINNO-406, a noval Bcr-Abl/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph? leukemia cells in the central nervous system, and cyclosporine A augments its in vivo actionBlood20071093061416954504
   PubMed Web of Science ®Google Scholar
• YoungMAShahNPChaoLHStructure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680Cancer Res20066610071416424036
   PubMed Web of Science ®Google Scholar
• ZauchaJMPrejznerWGiebelSImatinib therapy prior to myeloablative allogeneic SCTBone Marrow Transplant2005364172416007105
   PubMed Web of Science ®Google Scholar
• ZionMBen-YehudaDAvrahamAProgressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemiaProc Natl Acad Sci USA1994911072267938018
   PubMed Web of Science ®Google Scholar
• ZonderJAPembertonPBrandtHThe effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatmentClin Cancer Res200392092712796373
   PubMed Web of Science ®Google Scholar